<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850209</url>
  </required_header>
  <id_info>
    <org_study_id>2021SDU-QILU-067</org_study_id>
    <nct_id>NCT04850209</nct_id>
  </id_info>
  <brief_title>The Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori</brief_title>
  <official_title>The Impact of Interactive Patient Education Based on WeChat Group on the Eradication Rate of Helicobacter Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, effects of oral and written education, WeChat education plus oral and written&#xD;
      education on Helicobacter pylori eradication will be compared in a randomized way.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two randomized parallel groups in this study, control group and Wechat group.All of&#xD;
      the patients will be treated with Amoxicillin + Clarithromycin + Bismuth + Vonoprazan&#xD;
      fumarate. In control group,the patients will be educated by oral and written way about the&#xD;
      regimen. In Wechat group, the patients will be educated by Wechat oral and written way. Then,&#xD;
      the eradication rates, compliance, adverse events, patients' satisfaction and experience will&#xD;
      be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2021</start_date>
  <completion_date type="Anticipated">September 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There are two randomized parallel groups in this study, control group and Wechat group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The interventions are blind to follow-up personnel who collect and analyze compliance and the incidence of adverse events. The interventions are also blind to the UBT personnel.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>eradication rate in each group</measure>
    <time_frame>2 months</time_frame>
    <description>Six weeks after completion of treatment，number of patients get H.pylori eradicated supported by negative 13C-UBT results will be investigated by an independent researcher.Then eradication rate in each group will be calculated by using intention-to-treat analysis and per-protocol analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prevalence of adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>At the follow-up,adverse events complained by patients will be recorded by an independent researcher，meanwhile a 8 point visual analog scale (VAS) was used to evaluate severity of adverse events.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>compliance of patients in the two groups</measure>
    <time_frame>14 days</time_frame>
    <description>compliance was evaluated by assessing the total pills patients have taken.Compliance was defined as good when more than 80% or less than 120% of the total pills were taken.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">438</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Helicobacter Pylori Eradication</condition>
  <condition>Patient Education</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg , amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wechat group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg ,amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education. And patients will be invited into a Wechat group to obtain interactive education through question and answer,which is provided by medical professionals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oral and written education</intervention_name>
    <description>oral and written education</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Wechat group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Wechat group</intervention_name>
    <description>Wechat group: oral and written education plus Wechat group based interactive education provided by medical professional</description>
    <arm_group_label>Wechat group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. aged between 18 and 75 years old;&#xD;
&#xD;
          2. H. pylori infection confirmed by any two positive outcomes of rapid urease test (RUT),&#xD;
             13C-urea breath test (UBT) or histopathology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. previous therapy for H. pylori;&#xD;
&#xD;
          2. with significant underlying disease (e.g. decompensated liver cirrhosis, renal failure&#xD;
             or malignant tumors) that may interfere the study;&#xD;
&#xD;
          3. history of gastric surgery,&#xD;
&#xD;
          4. pregnancy or lactation;&#xD;
&#xD;
          5. the use of PPI or antibiotics during the 4 weeks prior to enrolment;&#xD;
&#xD;
          6. previous history of allergic reactions to any of the medications used in this&#xD;
             protocol;&#xD;
&#xD;
          7. unable to use smartphone and wechat&#xD;
&#xD;
          8. unwilling or incapable to provide informed consents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <phone>15588818685</phone>
    <email>zuoxiuli@sdu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu hosipital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>257000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuli Zuo, MD,PhD</last_name>
      <phone>15588818685</phone>
      <phone_ext>053188369277</phone_ext>
      <email>zuoxiuli@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yueyue Li, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Xiuli Zuo</investigator_full_name>
    <investigator_title>Professor, Director of gastroenterology department of Qilu hospital</investigator_title>
  </responsible_party>
  <keyword>helicobacter pylori</keyword>
  <keyword>eradication</keyword>
  <keyword>patient education</keyword>
  <keyword>Wechat group</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

